Elizabeth A Chrischilles1, Kathleen M Schneider2,3, Mary C Schroeder4, Elena Letuchy1, Robert B Wallace1, Jennifer G Robinson1, John M Brooks5. 1. Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa. 2. Schneider Research Associates, LLC, Des Moines, Iowa. 3. Buccaneer, A General Dynamics Company, West Des Moines, Iowa. 4. Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa. 5. Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina.
Abstract
OBJECTIVES: To determine whether function-related indicators (FRIs), derived from preadmission claims data, help explain the frequent practice of forgoing secondary prevention medications observed in Medicare. DESIGN: Retrospective cohort. SETTING: National Medicare data. PARTICIPANTS: Elderly Medicare beneficiaries discharged alive from an acute myocardial infarction (AMI) hospitalization in 2007-2008 (N = 184,156). MEASUREMENTS: Study outcomes were number of guideline-recommended secondary prevention medications (statins, beta-blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) used after discharge and 12-month survival. Preadmission data (FRIs, cardiovascular conditions, comorbid conditions), type of AMI (non-ST-elevation myocardial infarction, anterior, other), and procedures and complications during the hospitalization were from claims data. RESULTS: Function-related indicators (FRIs) were common before admission; 50% of individuals had at least one (range 0-11). After discharge, 85.8% used at least one class of guideline medication, and 30.2% used all three; 19.6% died within 12 months. Each additional FRI reduced the likelihood of receiving all three medication classes by 5% (adjusted odds ratio = 0.95, 95% confidence interval (CI) = 0.94-0.96) and increased 12-month mortality by 20% (adjusted hazard ratio (aHR) = 1.20, 95% CI = 1.19-1.21). Individuals taking all three classes of medication were 30% less likely to die within 12 months than those not taking guideline medications (aHR = 0.70, 95% CI = 0.67-0.73). Similar survival benefit was observed in individuals with and without functional impairments. CONCLUSION: Greater impairment in preadmission functional status, using a measure derived from claims data, was associated with less use of secondary prevention medications after AMI. Survival benefits of taking these medications were consistent across functional impairment levels.
OBJECTIVES: To determine whether function-related indicators (FRIs), derived from preadmission claims data, help explain the frequent practice of forgoing secondary prevention medications observed in Medicare. DESIGN: Retrospective cohort. SETTING: National Medicare data. PARTICIPANTS: Elderly Medicare beneficiaries discharged alive from an acute myocardial infarction (AMI) hospitalization in 2007-2008 (N = 184,156). MEASUREMENTS: Study outcomes were number of guideline-recommended secondary prevention medications (statins, beta-blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) used after discharge and 12-month survival. Preadmission data (FRIs, cardiovascular conditions, comorbid conditions), type of AMI (non-ST-elevation myocardial infarction, anterior, other), and procedures and complications during the hospitalization were from claims data. RESULTS: Function-related indicators (FRIs) were common before admission; 50% of individuals had at least one (range 0-11). After discharge, 85.8% used at least one class of guideline medication, and 30.2% used all three; 19.6% died within 12 months. Each additional FRI reduced the likelihood of receiving all three medication classes by 5% (adjusted odds ratio = 0.95, 95% confidence interval (CI) = 0.94-0.96) and increased 12-month mortality by 20% (adjusted hazard ratio (aHR) = 1.20, 95% CI = 1.19-1.21). Individuals taking all three classes of medication were 30% less likely to die within 12 months than those not taking guideline medications (aHR = 0.70, 95% CI = 0.67-0.73). Similar survival benefit was observed in individuals with and without functional impairments. CONCLUSION: Greater impairment in preadmission functional status, using a measure derived from claims data, was associated with less use of secondary prevention medications after AMI. Survival benefits of taking these medications were consistent across functional impairment levels.
Authors: Rony Lahoud; Michael Howe; Sangeetha M Krishnan; Sibin Zacharias; Elizabeth A Jackson Journal: Am J Cardiol Date: 2011-10-18 Impact factor: 2.778
Authors: Douglas S Lee; Jack V Tu; David N Juurlink; David A Alter; Dennis T Ko; Peter C Austin; Alice Chong; Therese A Stukel; Daniel Levy; Andreas Laupacis Journal: JAMA Date: 2005-09-14 Impact factor: 56.272
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: John E Morley; Bruno Vellas; G Abellan van Kan; Stefan D Anker; Juergen M Bauer; Roberto Bernabei; Matteo Cesari; W C Chumlea; Wolfram Doehner; Jonathan Evans; Linda P Fried; Jack M Guralnik; Paul R Katz; Theodore K Malmstrom; Roger J McCarter; Luis M Gutierrez Robledo; Ken Rockwood; Stephan von Haehling; Maurits F Vandewoude; Jeremy Walston Journal: J Am Med Dir Assoc Date: 2013-06 Impact factor: 4.669
Authors: Andrew R Zullo; Sadia Sharmin; Yoojin Lee; Lori A Daiello; Nishant R Shah; W John Boscardin; David D Dore; Sei J Lee; Michael A Steinman Journal: J Am Geriatr Soc Date: 2017-10-17 Impact factor: 5.562
Authors: Maarit J Korhonen; Jennifer G Robinson; Izabela E Annis; Ryan P Hickson; J Simon Bell; Juha Hartikainen; Gang Fang Journal: J Am Coll Cardiol Date: 2017-09-26 Impact factor: 24.094
Authors: Dongyu Zhang; Linn Abraham; Brian L Sprague; Tracy Onega; Shailesh Advani; Joshua Demb; Diana L Miglioretti; Louise M Henderson; Karen J Wernli; Louise C Walter; Karla Kerlikowske; John T Schousboe; Elizabeth Chrischilles; Dejana Braithwaite; Ellen S O'Meara Journal: Prev Med Date: 2021-11-09 Impact factor: 4.018
Authors: Dejana Braithwaite; Shama D Karanth; Christopher G Slatore; Dongyu Zhang; Jiang Bian; Rafael Meza; Jihyoun Jeon; Martin Tammemagi; Mattthew Schabath; Meghann Wheeler; Yi Guo; Bruno Hochhegger; Frederic J Kaye; Gerard A Silvestri; Michael K Gould Journal: BMJ Open Date: 2022-06-22 Impact factor: 3.006
Authors: Michael A Steinman; Andrew R Zullo; Yoojin Lee; Lori A Daiello; W John Boscardin; David D Dore; Siqi Gan; Kathy Fung; Sei J Lee; Kiya D R Komaiko; Vincent Mor Journal: JAMA Intern Med Date: 2017-02-01 Impact factor: 21.873
Authors: Jerry Suls; Elizabeth A Bayliss; Jay Berry; Arlene S Bierman; Elizabeth A Chrischilles; Tilda Farhat; Martin Fortin; Siran M Koroukian; Ana Quinones; Jeffrey H Silber; Brian W Ward; Melissa Wei; Deborah Young-Hyman; Carrie N Klabunde Journal: Med Care Date: 2021-08-01 Impact factor: 3.178
Authors: Dongyu Zhang; Linn Abraham; Joshua Demb; Diana L Miglioretti; Shailesh Advani; Brian L Sprague; Louise M Henderson; Tracy Onega; Karen J Wernli; Louise C Walter; Karla Kerlikowske; John T Schousboe; Ellen S O'Meara; Dejana Braithwaite Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-06-02 Impact factor: 4.254
Authors: Catherine Chioreso; Xiang Gao; Irena Gribovskaja-Rupp; Chi Lin; Marcia M Ward; Mary C Schroeder; Charles F Lynch; Elizabeth A Chrischilles; Mary E Charlton Journal: Ann Surg Date: 2021-10-01 Impact factor: 13.787
Authors: Cole B Haskins; Joan M Neuner; Bradley D McDowell; Ryan M Carnahan; Jess G Fiedorowicz; Robert B Wallace; Brian J Smith; Elizabeth A Chrischilles Journal: Clin Breast Cancer Date: 2019-09-30 Impact factor: 3.078